The content on this site is intended for healthcare professionals only
Early detection and prevention of melanoma (6/6)
Guidelines and recommendations for advanced melanoma (5/6)
Combination of newer agents in advanced melanoma (4/6)
Recent advances in advanced melanoma: BRAF inhibitors (3/6)
Recent advances in advanced melanoma: ipilimumab (2/6)
Metastatic melanoma: changes in epidemiology and current standards of care (1/6)
Development of lenvatinib for thyroid cancer
Health care issues in low and middle income countries.
Research from the Sarah Cannon Research Institute
Clinical research at Sarah Cannon UK
Role of vemurafenib in melanoma treatment
The changing landscape of melanoma therapies: indications of better patient outcome
Standard of care for ovarian cancer
Treatment options for ovarian cancer
2011 Gianni Bonadonna Breast Cancer Award and ASCO breast highlights
Investigating metabolism for cancer therapy
Importance of metastases in cancer growth
MD Anderson Institute of Personalised Cancer Therapy
Optimal therapy for children with high risk ALL
Treatment options for prostate cancer
ASCO 2011: Developments in ovarian cancer therapy
Ovarian cancer developments
Association of diabetes and cancer epidemiology
Sarah Canon Research Institute; overview and future
Links between cancer and weight, ethnic origin or social status
UN summit on non-communicable diseases
Olaparib maintenance therapy for ovarian cancer and updates from ICON7
New oncogene target for breast cancer: LMTK3
ASCO 2011: Key head and neck cancer research
Importance of geriatric oncology
PTEN expression does not diminish trastuzumab effectiveness
Combining oral targeted therapies shows early anti-tumour activity for advanced melanoma
Advances in breast cancer research from ASCO 2011
The ENERGY trial
Cancer prevention through education
Translational research from the Vall d'Hebron Institute of Oncology
Vall d´Hebron Institute of Oncology; advancing personalized and targeted therapies against cancer
Ethics of early-phase clinical trials
Suggested benefit of bevacizumab for newly diagnosed ovarian cancer patients at high risk of recurrence
New melanoma drug gives 63 percent reduction in risk of death compared to dacarbazine
Exemestane significantly reduces risk of invasive breast cancer in high-risk, postmenopausal women
Ipilimumab improves survival in metastatic melanoma
High dose chemotherapy helps combat neuroblastoma
Future for immunotherapies
Highlights from 2011 and ASCO’s future
ASCO 2011 highlights
